ReviewNature reviews. Clinical oncology2022
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome.
Review in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Nanomaterials targeting ferroptosis for osteoarthritis treatment: a systematic review of preclinical evidence.Journal of nanobiotechnology · 2026Pooled it
- First-in-human controlled inhalation of thin graphene oxide nanosheets to study acute cardiorespiratory responses.Nature nanotechnology · 2024Trial
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Leveraging nanoparticle protein corona to advance plasma proteome profiling.Nature communications · 2026Review
- Influence of protein aggregates, extracellular vesicles, and lipoprotein fusion on ionizable lipid nanoparticles protein corona analysis.Nature communications · 2026Review
- Body Mass Index-Specific Nanoparticle Protein Corona Signatures in Late Pregnancy.bioRxiv : the preprint server for biology · 2026Article
- Combined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis.Cell reports. Medicine · 2026Article
- MXene-Protein Corona Interfaces for Molecular Profiling of Alzheimer's Disease.bioRxiv : the preprint server for biology · 2026Article
- Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA and Protein Biomarkers.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity.Communications medicine · 2026Article
- Ensemble learning on serum metabolic fingerprints for early detection of lung adenocarcinoma.NPJ precision oncology · 2026Article
- Flower-like Silver Bismuth Sulfide/Carbon Nanosphere Nanocomposite for Sensitive Electrochemical Tumor Marker Sensing.ACS measurement science au · 2026Article
- Review
- Evolution of Multivalent Aptamer Corona for High-Throughput Multiplexed Detection of Multiple Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut-Brain Axis Dysregulation in Inflammatory Bowel Disease: Implications for Coagulation Abnormalities and Extraintestinal Manifestations.International journal of general medicine · 2026Review
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.International journal of nanomedicine · 2026Review
- Improving accuracy and reproducibility of mass spectrometry characterization of protein coronas on nanoparticles.Nature protocols · 2025Review
- Advances in biomonitoring technologies for women's health.Nature communications · 2025Review
- Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances.The journal of liquid biopsy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Over the past decade, the development of 'simple' blood tests that enable cancer screening, diagnosis or monitoring and facilitate the design of personalized therapies without the need for invasive tumour biopsy sampling has been a core ambition in cancer research. Data emerging from ongoing biomarker development efforts indicate that multiple markers, used individually or as part of a multimodal panel, are required to enhance the sensitivity and specificity of assays for early stage cancer detection. The discovery of cancer-associated molecular alterations that are reflected in blood at multiple dimensions (genome, epigenome, transcriptome, proteome and metabolome) and integration of the resultant multi-omics data have the potential to uncover novel biomarkers as well as to further elucidate the underlying molecular pathways. Herein, we review key advances in multi-omics liquid biopsy approaches and introduce the 'nano-omics' paradigm: the development and utilization of nanotechnology tools for the enrichment and subsequent omics analysis of the blood-circulating cancerome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.